CN103006679A - Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria - Google Patents
Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria Download PDFInfo
- Publication number
- CN103006679A CN103006679A CN201210550179.9A CN201210550179A CN103006679A CN 103006679 A CN103006679 A CN 103006679A CN 201210550179 A CN201210550179 A CN 201210550179A CN 103006679 A CN103006679 A CN 103006679A
- Authority
- CN
- China
- Prior art keywords
- baicalin
- preparation
- application
- medicine
- ndm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 title claims abstract description 40
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 title claims abstract description 40
- 229960003321 baicalin Drugs 0.000 title claims abstract description 40
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 241000894006 Bacteria Species 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 59
- 229940079593 drug Drugs 0.000 title claims description 33
- 238000002360 preparation method Methods 0.000 title claims description 21
- 239000008923 Qingkailing Substances 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010048723 Multiple-drug resistance Diseases 0.000 title 1
- 101000740455 Klebsiella pneumoniae Metallo-beta-lactamase type 2 Proteins 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 241000588724 Escherichia coli Species 0.000 claims abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 9
- 241000588902 Zymomonas mobilis Species 0.000 claims description 8
- 241000588624 Acinetobacter calcoaceticus Species 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 241000588626 Acinetobacter baumannii Species 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 241000122973 Stenotrophomonas maltophilia Species 0.000 abstract description 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000589291 Acinetobacter Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 208000031729 Bacteremia Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- MOFOLNOWFPVLGZ-BHWDSYMASA-N (2s,3s,4s,5r,6s)-6-(5,8-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC=CC=3)OC2=C1O MOFOLNOWFPVLGZ-BHWDSYMASA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 101100111649 Klebsiella pneumoniae blaNDM-1 gene Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010034752 beta-lactamase NDM-1 Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- -1 electuary Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108010074858 plaferon Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to an active component baicalin of a Qingkailing compound, which has an inhibiting effect on acinetobacter calcoaceticus, acinetobacter baumannii, A.baumannii, stenotrophomonas maltophilia and escherichia coli containing NDM-1 drug resistance gene, so that the active component baicalin can be used for inhibiting these bacterial diseases and treating and/or preventing diseases caused by these bacteria.
Description
Technical field
The present invention relates to a kind of new medical usage of baicalin, specifically prepare application in the anti-multi-drug resistant bacteria medicine at baicalin.
Background technology
Multi-drug resistant bacteria (multiple resistant bacteria) refers to the pathogen of multi-drug resistant, i.e. a kind of microorganism is to three classes (such as aminoglycoside, erythromycin, beta-lactam class) or drug resistance of above antibiotic while of three classes.Wherein the most common is Acinetobacter bauamnnii and the Pseudomonas aeruginosa that occurs among NDM-1, MDR-TB, MDR-MRSA and the ICU that is everlasting.NDM-1(New Delhi metallo-β-lactamase-1, the New Delhi metallo-β-lactamase), have another name called the NDM-1 antibacterial, be a kind of enzyme of Carbapenem-resistant class.The NDM-1 gene is often carried by plasmid, but also is incorporated on the chromosome of antibacterial, is easy to propagate between different bacterial strains and diffusion, and the protein monomer molecular weight of NDM-1 coding is 28kDa, and the sequence similarity of its sequence and other MBL is very low.NDM-1 mainly is distributed in enterobacteriaceae and the Acinetobacter bauamnnii, and the antibacterial of carrying NDM-1 not only comprises conditioned pathogen, also comprises pathogenic bacterium, such as common shigella, cholera, pseudomonas aeruginosa etc.It has the height drug resistance, almost can be hydrolyzed clinical line antibacterials commonly used, comprises beta-lactam, carbapenems, fluoroquinolones, aminoglycoside etc.For a long time, the abuse of antibiotic medicine is the major reason that expedites the emergence of multi-drug resistant bacteria.At present, multi-drug resistant bacteria infects and presents growth trend, but the Antimicrobial drug choice scheme seldom, and therefore heavy drug-fast bacteria infection has become global thorny problem.
Baicalin (the extract of the dry root of labiate Radix Scutellariae Scutellaria baicalensis Georgi, pressing dry product calculates, contain baicalin (C21H18O11) injection and must not be less than 90.0%) be the primary raw material medicine of heat-clearing and toxic substances removing herbal mixture QINKAILING ZHUSHEYE, have the effects such as antibacterial, diuresis, function of gallbladder promoting, antiinflammatory, resistance attitude, spasmolytic, the clinical hepatitis that is used for the treatment of all has obvious curative effects to acute icteric, acute non-icteric type and chronic hepatitis.The how better medical efficacy of R and D baicalin is one of the important subject in many Chinese medicine and pharmacies field.
Summary of the invention
Purpose of the present invention is exactly to develop the novel medical use of baicalin, provides a kind of effectively medicine of antagonism multi-drug resistant bacteria for clinical simultaneously.
The present inventor finds that through studying for a long period of time baicalin has significantly inhibitory action to containing NDM-1 drug resistant gene antibacterial, and be directly proportional with drug level, thereby invented a kind of new medical usage of baicalin, namely finished the application of baicalin in the anti-multi-drug resistant bacteria medicine of preparation.
Baicalin described in the present invention can be buied from crude drug commercial distribution channel.
The baicalin raw material can be prepared into the pharmaceutical preparatioies such as granule, electuary, injection, capsule, tablet according to the described method of prior art.
Multi-drug resistant bacteria described in the present invention refers to contain the multi-drug resistant bacteria of NMD-1 gene, comprise acinetobacter calcoaceticus (Acinetobacter calcoaceticus), Acinetobacter bauamnnii (Acinetobacter baumannii, A.baumannii), have a liking for the narrow food Zymomonas mobilis of Fructus Hordei Germinatus oligotrophy (Stenotrophomonas maltophilia) or contain NDM-1 drug resistant gene escherichia coli (Escherichia coli).
It is gram negative bacteria that the above-mentioned NDM-1 of containing drug resistant gene detects bacterial strain, has stronger pathogenic and antibiotic resistance.Wherein, acinetobacter calcoaceticus and Acinetobacter bauamnnii can cause pulmonary infection, wound and skin infection, urogenital infections, bacteremia bacteremia, meningitis etc., the narrow food Zymomonas mobilis of Fructus Hordei Germinatus oligotrophy can cause serious respiratory system infection etc., contains NDM-1 drug resistant gene escherichia coli and can cause to intestinal infection and to antibiotic and have Drug resistance.
Further, the present invention also provides the application of baicalin in the anti-acinetobacter calcoaceticus medicine of preparation, and namely baicalin treats and/or prevents application in the medicine of the disease that acinetobacter calcoaceticus causes in preparation.
Further, the present invention also provides the application of baicalin in the anti-Acinetobacter bauamnnii medicine of preparation, and namely baicalin treats and/or prevents application in the medicine of the disease that Acinetobacter bauamnnii causes in preparation.
Further, the present invention also provides baicalin in the anti-application of having a liking in the narrow food Zymomonas mobilis of the Fructus Hordei Germinatus oligotrophy medicine of preparation, and namely baicalin treats and/or prevents application in the medicine of having a liking for the microbial disease of the narrow food unit cell of Fructus Hordei Germinatus oligotrophy in preparation.
Further, the present invention also provides baicalin in the anti-application that contains in the NDM-1 drug resistant gene antibacterial medicine of preparation, and namely baicalin treats and/or prevents application in the medicine that contains the disease that NDM-1 drug resistant gene escherichia coli cause in preparation.
Baicalin preparation of the present invention can be used for treating above-mentioned disease by containing the initiation of NDM-1 drug resistant gene multidrug resistant antibacterial, as contain intestinal infection, respiratory system infection, wound and skin infection that NDM-1 drug resistant gene multidrug resistant antibacterial causes, urogenital infections, bacteremia bacteremia, meningitis etc., especially be applicable to treat by acinetobacter calcoaceticus, Acinetobacter bauamnnii, have a liking for the narrow food Zymomonas mobilis of Fructus Hordei Germinatus oligotrophy or contain the disease that NDM-1 drug resistant gene escherichia coli cause.
Pharmaceutical preparation of the present invention can be definite according to clinical experiment and patient's concrete condition during its concrete consumption when using as purposes of the present invention, also can be with reference to baicalin preparation 2-5 dosage administration doubly.
Specific embodiments
Further set forth by the following examples the beneficial effect of medicine of the present invention with test example.
Effect test
The detection bacterial strain that this pharmacodynamics test adopts: acinetobacter calcoaceticus (Acinetobacter calcoaceticus, A.calcoaceticus), Acinetobacter bauamnnii (Acinetobacter baumannii, A.baumannii) and have a liking for narrow food Zymomonas mobilis (the Stenotrophomonas maltophilia of Fructus Hordei Germinatus oligotrophy, S.maltophilia), all contain the blaNDM-1 drug resistant gene; PGEX-4T-NDM1-DH5 α is the escherichia coli (Escherichia coli, E.coli) that contain the NDM-1 recombiant plasmid; PGEX-4T-NDM-1-BL21(expresses NDM-1 in e. coli bl21) be the escherichia coli (Escherichia coli, E.coli) that contain the NDM-1 recombiant plasmid, on its plasmid with the GST label.Above-mentioned bacterial strains provides by Diseases Preventing and Controlling Institute.
Test example 1
The baicalin extract is to containing the fungistatic effect research of NDM-1 drug resistant gene antibacterial
The test sample that this pharmacodynamics test adopts: baicalin is commercially available, meets the Chinese Pharmacopoeia standard, need add an amount of water for injection during test, stirs to make suspendible, then slowly adds while stirring 5% sodium hydroxide solution to baicalin and all dissolves.
Preparation LB agar culture medium when high pressure is cooled to 60 ℃, is got the baicalin extract, press the 1:9(medicine: LB, V/V) ratio preparation variable concentrations medicine (0.005g/ml, 0.01g/ml, 0.015g/ml) flat board, agar thickness 3-4mm, the preparation medicine is dull and stereotyped, for subsequent use.
The research baicalin carries out bacteriostatic experiment to containing NDM-1 drug resistant gene antibacterial:
4 strains are contained NDM-1 gene Resistant strain acinetobacter calcoaceticus, Acinetobacter bauamnnii, have a liking for the narrow food Zymomonas mobilis of Fructus Hordei Germinatus oligotrophy and escherichia coli pGEX-4T-NDM1-DH5 α is inoculated in respectively in the LB fluid medium that contains 16 μ g/ml imipenums, 37 ℃, 200rpm overnight incubation, after next day, bacterium liquid diluted 10 times with aseptic PBS buffer, drawing respectively 2 μ l is inoculated in the medicine agar plate surface or adopts the method for scoring inoculation, flat board places 37 ℃ to hatch about 24h, observe each strain growth situation, get the biocidal property measurement result of Fructus Gardeniae extract, see Table 1.
Adopt agar dilution that the minimal inhibitory concentration (MIC) of baicalin extract is measured, Resistant strain is inoculated on the agar plate of different pharmaceutical concentration, hatch about 24h for 37 ℃, observe each strain growth situation, the minimum drug level (MIC value) that the inhibition bacterial strain can not be grown is respectively acinetobacter calcoaceticus 0.015g/ml, Acinetobacter bauamnnii 0.02g/ml, has a liking for the narrow food Zymomonas mobilis of Fructus Hordei Germinatus oligotrophy 0.005g/ml, pGEX-4T-NDM-1-BL21〉0.02g/ml.
Experimental result shows: baicalin all has inhibitory action to Resistant strain, and along with the increase of drug level, inhibitory action obviously strengthens, and illustrate that baicalin has inhibitory action to containing NDM-1 drug resistant gene fastbacteria, and fungistatic effect is obvious; Medicine is different to the antibacterial ability that difference detects bacterial strain, and MIC is difference to some extent also, has the anti-ability that contains NDM-1 drug resistant gene fastbacteria of stronger wide spectrum.
Table 1 baicalin extract concentrations is on the impact of bacterial strain
Annotate: +++expression does not suppress growth, ++ expression suppresses not obvious, and+expression obviously suppresses, and-expression suppresses fully, does not grow.
Claims (6)
1. the application of baicalin in the medicine of the anti-multi-drug resistant bacteria of preparation.
2. baicalin is in the anti-application that contains in the NDM-1 drug resistant gene antibacterial medicine of preparation.
3. the application of baicalin in the anti-acinetobacter calcoaceticus medicine of preparation.
4. the application of baicalin in the anti-Acinetobacter bauamnnii medicine of preparation.
5. baicalin is in the anti-application of having a liking in the narrow food Zymomonas mobilis of the Fructus Hordei Germinatus oligotrophy medicine of preparation.
6. baicalin is in the anti-application that contains in the NDM-1 drug resistant gene escherichia coli medicine of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550179.9A CN103006679B (en) | 2012-12-17 | 2012-12-17 | Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550179.9A CN103006679B (en) | 2012-12-17 | 2012-12-17 | Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103006679A true CN103006679A (en) | 2013-04-03 |
| CN103006679B CN103006679B (en) | 2014-06-18 |
Family
ID=47956145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210550179.9A Active CN103006679B (en) | 2012-12-17 | 2012-12-17 | Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103006679B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989693A (en) * | 2013-09-18 | 2014-08-20 | 吉林大学 | Application of scutelloside in preparation of acute hemolytic uremic syndrome treatment drugs |
| CN104473954A (en) * | 2014-11-19 | 2015-04-01 | 中国药科大学 | Application of baicalin as metal beta-lactamase inhibitor |
| CN116098914A (en) * | 2023-03-21 | 2023-05-12 | 青岛农业大学 | Composition and medicine for preventing and treating stenotrophomonas maltophilia |
-
2012
- 2012-12-17 CN CN201210550179.9A patent/CN103006679B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 汪东海等: "黄芩苷消除鲍曼不动杆菌耐药质粒的实验研究", 《中国现代应用药学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989693A (en) * | 2013-09-18 | 2014-08-20 | 吉林大学 | Application of scutelloside in preparation of acute hemolytic uremic syndrome treatment drugs |
| CN103989693B (en) * | 2013-09-18 | 2017-04-12 | 湖北武当动物药业有限责任公司 | Application of scutelloside in preparation of acute hemolytic uremic syndrome treatment drugs |
| US9629864B2 (en) | 2013-09-18 | 2017-04-25 | Hubei Wudang Animal Pharmaceutical Co., Ltd. | Use of baicalin in preparation of drugs for treating acute hemolytic uremic syndrome |
| CN104473954A (en) * | 2014-11-19 | 2015-04-01 | 中国药科大学 | Application of baicalin as metal beta-lactamase inhibitor |
| CN116098914A (en) * | 2023-03-21 | 2023-05-12 | 青岛农业大学 | Composition and medicine for preventing and treating stenotrophomonas maltophilia |
| CN116098914B (en) * | 2023-03-21 | 2023-10-24 | 青岛农业大学 | Composition and medicine for preventing and treating stenotrophomonas maltophilia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103006679B (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | In vitro and in vivo evaluation of an exopolysaccharide produced by Lactobacillus helveticus KLDS1. 8701 for the alleviative effect on oxidative stress | |
| Hou et al. | Helicobacter pylori biofilm-related drug resistance and new developments in its anti-biofilm agents | |
| Alshami et al. | Antimicrobial activity of Hibiscus sabdariffa extract against uropathogenic strains isolated from recurrent urinary tract infections | |
| EP2881113B1 (en) | New application of pogostone | |
| Shahwany et al. | Antibacterial and anti-biofilm activity of three phenolic plant extracts and silver nanoparticles on Staphylococcus aureus and Klebsiella pneumoniae | |
| CN103006679B (en) | Application of active component baicalin of Qingkailing compound in preparation of medicines resisting multiple drug-resistance bacteria | |
| Lou et al. | Separation and enrichment of burdock leaf components and their inhibition activity on biofilm formation of E. coli | |
| Bokaeian et al. | Antibacterial activity of silver nanoparticles produced by plantago ovata seed extract against antibiotic resistant Staphylococcus aureus | |
| CN104383047B (en) | Applications of Cape Jasmine extract in preparation of anti-Acinetobacter baumannii drug | |
| CN102475703A (en) | Anti-Acinetobacter baumannii drug combination and application thereof | |
| CN107961260A (en) | Treatment, the medicament for preventing birds coliform diarrhea disease and preparation method thereof | |
| CN103040897B (en) | Application of Qingkailing active component radix isatidis extract in preparation of anti-multidrug-resistant bacterium medicine | |
| CN105998153A (en) | Application of pithecellobium clypearia extract to preparation of drug for resisting generation of extended spectrum beta-lactamase escherichia coli | |
| CN106619829A (en) | Medicine with resistance to staphylococcus aureus as well as preparation method and application of medicine | |
| CN105663126B (en) | The antifungal products of ambroxol hydrochloride joint Fluconazole and its application | |
| CN109125399A (en) | The antibacterial action of stephania tetrandra extract | |
| CN102349896B (en) | Pharmaceutical composition of imipenem, cilastatin and sulbactam | |
| CN102670674A (en) | Geranium strictipes R. Knuth effective part extract as well as preparation method and drug application | |
| CN103006846A (en) | Application of Qingkailing to preparation of medicament against multiple resistant bacteria | |
| CN102988456A (en) | Application of honeysuckle extractive from active components of Qingkailing for preparing multiple-resistant bacteria resistant medicine | |
| CN105998029A (en) | Antibacterial composite drug of levofloxacin hydrochloride for injection | |
| CN100363056C (en) | Medicine for treating upper respiratory tract infection | |
| CN102988537B (en) | Application of Cape jasmine extractive from active components of Qingkailing for preparing multiple-resistant bacteria resistant medicine | |
| CN110960545A (en) | Application of punicalagin in inhibiting growth of multidrug-resistant klebsiella pneumoniae | |
| CN103110746A (en) | Effective antibacterial traditional chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |